Navigation Links
Stemedica Enters into Stem Cell Licensing Agreement with Kalbe Farma
Date:4/25/2013

San Diego, CA (PRWEB) April 25, 2013

Stemedica Asia PTE, LTD, a wholly owned subsidiary of Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced that the Company has entered into a definitive licensing agreement with the Stem Cell and Cancer Institute, a division of PT Kalbe Farma Tbk. (Kalbe). Under the terms of the Agreement Kalbe shall be the exclusive licensor of Stemedica’s ischemic tolerant adult allogeneic mesenchymal and neural stem cells for use in clinical trials in Indonesia, Philippines and Thailand. The Agreement also provides Kalbe with first rights of refusal for additional countries including Singapore, Malaysia, Vietnam, Brunei, Cambodia, Laos and Myanmar. Kalbe’s Stem Cell and Cancer Institute shall be responsible for organizing and funding clinical trials in Southeast Asia.

Headquartered in Central Jakarta, Indonesia, Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with close to US $6.5 billion in market capitalization as of Q1 2013. Established in 1966, Kalbe has expanded by strategic acquisitions of companies involved in prescription and over-the-counter pharmaceuticals, energy drinks and nutritional products. Kalbe’s Prescription Pharmaceutical Division features a complete product range including the manufacture of generics and licensed drugs. Pharma Metric Labs, a Kalbe company, is an independent Contract Research Organization (CRO) providing global studies in oncology, monoclonal antibodies and stem cells. Kalbe’s packaging and distribution capabilities allow the company to reach over one million outlets with their brands.

Kalbe’s Stem Cell and Cancer Institute was established in 2006 as part of Kalbe’s founder Dr. Boenjamin Se
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stemedica Issued U.S. Patent For Stem Cell Treatment of Diabetic Retinopathy and Diabetic Optic Neuropathy
2. Stephen Epstein, MD To Head Scientific & Medical Advisory Board For Stemedica’s Cardiology Division
3. Emory Cardiologists Arshed Quyyumi And Javed Butler Join Stemedica Cardiology Division Scientific Advisory Board
4. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
5. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
6. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
7. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
8. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
9. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
10. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
11. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial ... announce a new genetic test built upon research from ... Test will provide physicians with an objective way ... levels are stratified between individuals. With this new test, ... has a genetic predisposition that will affect their pain ...
(Date:9/30/2014)... Sept. 30, 2014 CORD:USE Cord Blood Bank ... that it has entered into an Equity and Exclusive ... has licensed a series of patented technologies for the isolation ... clinical applications.  Tianhe is performing Phase I/II clinical trials ... Spain using Tianhe,s Stem Cell Educator Therapy ...
(Date:9/30/2014)... 2014 OriginOil Inc. (OTC/QB: OOIL), developer ... to clean up large quantities of water, announced today ... reported on the launch of the company's CLEAN-FRAC™ industrial ... by partner STW Resources . , Immediately upon ... day (bpd) and achieved a 99.8% reduction in Turbidity ...
(Date:9/30/2014)... 30, 2014 FemCap Inc., www.femcap.com  an ... receipt of a patent No: US, 8,795,248 B2 dated ... received FDA clearance in the U.S., 510(K) K121857, medical ... Europe. This patent is related to its menstrual cup with ... company is releasing FemmyCycle Teen, a third menstrual cup ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2The FemmyCycle 2
... NEW YORK, Nov. 6 Morria Biopharmaceuticals,Plc, a ... positive data from its ICH compliant Phase II ... from allergic,rhinitis. MRX-4 was given as an intranasal ... study was conducted in allergic,rhinitis patients outside of ...
... world leadership in the ... ingredients, - New S2383 flavor enhancer may be used in beverages, ... healthcare products to reduce the need for sucralose, ... (Nasdaq: SNMX ), a leading company,focused on using proprietary technologies ...
... NOVATO, Calif., Nov. 6 BioMarin,Pharmaceutical Inc. (Nasdaq: ... clinical,studies of Kuvan(R) (sapropterin dihydrochloride), Naglazyme(R),(galsulfase) and enzyme ... disease will be presented at the 58th Annual ... in Philadelphia,Pennsylvania, November 11-15, 2008., "We look ...
Cached Biology Technology:Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 2Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics 2Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics 3
(Date:10/1/2014)... rainforests, prairies and forests of the world can also ... according to a surprising new study led by Colorado ... , The research team analyzed 596 soil samples collected ... stunning diversity of below-ground life, most of which had ... to 16.2 percent of the organisms discovered in the ...
(Date:9/30/2014)... is published today in the first authoritative scientific study ... on both sides of the grouse moor management debate. ... the Ecohydrology of River basins) project has shown that ... support red grouse populations for gun sports, has significant ... properties, river water chemistry and river ecology. , A ...
(Date:9/30/2014)... as something that we enjoy when we visit a national ... think of ourselves as a part of nature? A bird,s ... house? , The answers to these questions reflect different ... speech and in cultural artifacts. , A new Northwestern University ... Indian Center of Chicago and the Menominee tribe of Wisconsin, ...
Breaking Biology News(10 mins):Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3Grouse moor burning causes widespread environmental changes 2The cultural side of science communication 2
... . , Halle/Saale. Invasive plant species can flourish ... origin. The reasons for this can be genetic changes or ... to adapt to the newcomers. These are the conclusions of ... their research on Buddleia or the Butterfly bush (Buddleja davidii) ...
... Stanford researchers have joined the ranks of investigators for ... 14 current HHMI investigators at Stanford, 11 of which ... HHMI investigators nationwide. Stanford,s recipients are: , ... applied physics. His research group is seeking to understand ...
... linked to lung disease may have a 70-percent to ... report in the May 26 issue of Archives of ... disorder, alpha1-antitrypsin deficiency (1ATD), is one of the most ... those of European descent, according to background information in ...
Cached Biology News:When the butterfly bush blossoms 2When the butterfly bush blossoms 34 Stanford faculty named Howard Hughes Medical Institute Investigators 2Genetic mutation associated with increased risk of lung cancer 2
...
... XT is undoubtedly the most complete and ... concept of layers and subsets makes it ... for different data outputs, for example Cy3 ... as well as different subsets of genes ...
...
...
Biology Products: